FINHUB Insights

ABBV · Q1 FY25 · Jan 1 – Mar 31, 2025

AbbVie Q1 FY25: where the revenue came from and where it went

AbbVie Q1 FY25: revenue $13.3B (+8% year over year). Net profit $1.3B. Largest cohort Skyrizi $3.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 1 – Mar 31, 2025
Reported
May 9, 2025 10-Q
Sankey diagram of AbbVie's income statement for Q1 FY25: revenue of $13.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$13.3B +8% year over year
Gross profit$9.3B 70% margin
Operating profit$3.7B 28% margin
Net profit$1.3B 10% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 13.3 100% +8%
Skyrizi 3.4 26%
Neuroscience 2.3 17%
Rinvoq 1.7 13%
Oncology 1.6 12%
Other 1.3 10%
Humira 1.1 8%
Aesthetics 1.1 8%
Other Key Products 0.8 6%
Cost of revenue−430%
Gross profit9.370% margin+3pp
SG&A−3.325%−2pp
Other−2.317%+0pp
Operating profit3.728% margin+5pp
Tax−0.4
Interest & other costs−2
Net profit1.310%−1pp
Filing on EDGAR More quarters of ABBV

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters